FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
New antibiotic development: barriers and opportunities
3605PDF: 1983HTML: 2053 -
The impact of tocilizumab on hepatic enzyme levels in rheumatoid arthritis patients: a narrative review
1281PDF: 360SUPPLEMENTARY MATERIAL: 124HTML: 48 -
Biomarkers for sepsis: past, present and future
2757PDF: 1252HTML: 1198 -
Open questions on bioequivalence: the case of cholecalciferol
2286PDF: 1339HTML: 1121 -
White-coat hypertension and masked hypertension: an update
2022PDF: 1147HTML: 1017 -
Adult onset Still's disease: a comparison of two clinical cases
1978PDF: 1020HTML: 496 -
Sex-gender and atrial fibrillation treatment in the AntiThrombotic Agents in Atrial Fibrillation (ATA-AF) study
1977PDF: 1568Appendix: 774HTML: 549 -
-
Pharmacological interactions in novel oral anticoagulants, statins, and hypertension drugs in patients treated with direct-acting antivirals for hepatitis C: a Delphi Consensus project
1394PDF: 540SUPPLEMENTARY MATERIAL: 309ACKNOWLEDGMENTS: 264HTML: 171 -
-
Postprandial hyperglycemia: a new frontier in diabetes management?
3006PDF: 1686HTML: 3388 -
Hypertension and emergency medicine: an update
2070PDF: 976HTML: 389 -
Acetylsalicylic acid in primary prevention: a review
950PDF: 620HTML: 488 -
Cardiovascular risk factors in sub-Saharan Africa: a review
3083PDF: 1388HTML: 1537 -
Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?
2308PDF: 729SUPPLEMENTARY MATERIAL: 348HTML: 112 -
-
P101 | Metainflammation and coagulation response of the obese patients during sepsis: an observational-prospective study L. Molinari1, A. Di Vincenzo2, B. Barbato2, C. Purificati2, A. Postal2, S. Pavone2, M. Marchegiani2, S. Cuppini1, L. Spiezia3, R. Vettor2 | 1Medicina Interna, Azienda Ospedaliera di Rovigo, 2Clinica Medica 3, Azienda Università degli Studi di Padova, 3Medicina Generale, Azienda Università degli Studi di Padova, Italy
184 -
Cytokine profile in COVID-19 infection: focus on interleukin-13, interleukin-33, and tumor necrosis factor-α as immunological markers
997PDF: 497SUPPLEMENTARY MATERIAL: 239HTML: 101 -
Pregnancy and heart disease: what Internists should know
1671PDF: 828HTML: 280 -
Complexity of patients with chronic obstructive pulmonary disease hospitalized in internal medicine: a survey by FADOI
2227PDF: 1079Appendix: 586HTML: 695 -
Inappropriate testing for the diagnosis of coronary artery disease
1688PDF: 1028HTML: 754 -
CO20 | Oral semaglutide for 12 months improves microalbuminuria and GFR in type 2 diabetes outpatients A.M. Labate1, L. Moretti2, M.L. Spina3, E. Allemand2, P. Villari4 | 1ASST Mantova Specialistica Ambulatoriale Borgo Mantovano (MN), 2ASST Garda UOC Medicina Interna Po Gavardo (BS), 3ASST Mantova Specialistica Ambulatoriale Asola (MN), 4ASST Garda Specialistica Ambulatoriale Po Leno (BS), Italy
245 -
Screening of the key genes and signaling pathways for schizophrenia using bioinformatics and next generation sequencing data analysis
3241PDF: 660SUPPLEMENTARY MATERIAL: 255HTML: 15 -
The clinical impact of hypoglycemia in hospitalized patients
2424PDF: 1108HTML: 1000 -
CO27 | Pseudomonas aeruginosa MDR strain bacteraemia successfully treated with piperacillin/tazobactam: when beta-lactam continuous infusion, therapeutic drug monitoring and fosfomycin combination make everything easier A. Pagotto1, A. Acquasanta1, L. Martini1, A. Sartor2, C. Tascini1 | 1Infectious Diseases Division, Department of Medicine (DAME), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, 2Microbiology Unit, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
249 -
-
The erectile dysfunction as a cardiovascular risk factor
1758PDF: 1043HTML: 1574 -
Legal value of clinical competence and its certification
1122PDF: 704HTML: 192 -
Stroke prevention in atrial fibrillation: findings from Tuscan FADOI Stroke Registry
1831PDF: 1400Appendix: 635HTML: 630 -
P41 | Efficacy and safety of Roxadustat in patients with anemia of dialysis-dependent chronic kidney disease with or without inflammation: pooled analysis of four phase 3 studies G. Choukroun1, A. Harkavyi2, V. Santos3, A. Jiletcovici3, L. Del Vecchio4 | 1CHU Amiens Picardie and Jules Verne University, Amiens, France, 2Astellas Pharma Europe, Addlestone, UK, 3Astellas Pharma, Inc., Northbrook, USA, 4Sant’Anna Hospital, ASST Lariana, Como, Italy
381
